Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome by Toft-Petersen, Marie et al.
Unravelling the relevance of CLEC12A as a cancer stem cell
marker in myelodysplastic syndrome
Marie Toft-Petersen,1 Line Nederby,1
Eigil Kjeldsen,1 Gitte B. Kerndrup,2
Gordon D. Brown,3 Peter Hokland1 and
Anne Stidsholt Roug1
1Department of Haematology, Aarhus University
Hospital, 2Department of Pathology, Aarhus
University Hospital, Aarhus, Denmark and
3Immunity, Infection and Inflammation
Programme, Institute of Medical Sciences,
University of Aberdeen, Aberdeen, UK
Received 18 March 2016; accepted for
publication 9 June 2016
Correspondence: Marie Toft-Petersen,
Department of Haematology, Aarhus
University Hospital, Tage-Hansens Gade 2,
entrance 4A, 2nd floor, DK-8000 Aarhus C,
Denmark.
E-mail: marie.toft-petersen@clin.au.dk
Summary
Evidence of distinct disease propagating stem cells in myelodysplastic syn-
drome (MDS) has emerged in recent years. However, immunophenotypic
characterization of these cancer stem cells remains sparse. In acute myeloid
leukaemia (AML), we have previously described aberrant expression of the
C-type lectin domain family 12, member A (CLEC12A) as a stable and reli-
able marker of leukaemia blasts and as a tool for assessing minimal residual
disease. Furthermore, CLEC12A has been proposed as a promising marker
of leukaemic stem cells in AML. The role of CLEC12A in MDS, however,
remains to be elucidated. In this study, we found CLEC12A aberrantly
expressed on the CD34+CD38 cell compartment in 71% (22/31) of MDS
patients, distributed across all Revised International Prognostic Scoring Sys-
tem risk groups. We showed that the CD34+CD38CLEC12A+ cells were
indeed malignant and possessed functional stem cell properties in the long-
term colony-initiating cell assay. As opposed to reported findings in AML,
we showed that cancer stem cells from MDS samples derived from both
CLEC12A positive and negative CD34+CD38 subpopulations. Due to the
absence of CLEC12A on normal haematopoietic stem cells, CLEC12A stem
cell immunophenotyping may contribute to diagnosing and monitoring
MDS patients and could furthermore add knowledge about disease propa-
gating cells in MDS.
Keywords: cancer stem cells, myelodysplastic syndrome, hMICL, CD371,
LTC-IC.
Myelodysplastic syndrome (MDS) is a heterogeneous group
of clonal diseases marked by dysplasia in the bone marrow
(BM) causing cytopenias in the peripheral blood (PB) and
with an inherent tendency to progress to acute myeloid leu-
kaemia (AML). Diagnosis remains a challenge and relies on
morphological and cytogenetic evaluation after the exclusion
of other causes of cytopenias. When the morphological dys-
plastic features are mild or even absent and PB cytopenias
are persistent the diagnosis is termed idiopathic cytopenias
of undetermined significance (ICUS) (Valent et al, 2012;
Bejar & Steensma, 2014). Evaluating myelodysplastic features
using flow cytometry is a growing field of interest and highly
sensitive multicolour immunophenotypic profiling and
accompanying scoring systems have proven useful in MDS,
both in diagnostic and prognostic terms (Ogata et al, 2006;
van de Loosdrecht et al, 2008).
The concept of the leukaemic stem cell (LSC) is well
established in AML and the frequency of the CD34+CD38
stem cell compartment with aberrant marker expression has
proven predictive of adverse outcome in several studies (Ver-
gez et al, 2011; Terwijn et al, 2014). Following the seminal
studies by Bakker et al (2004), we have identified the C-type
lectin domain family 12, member A (CLEC12A) (also named
hMICL and CLL-1) as a stable and reliable leukaemia-asso-
ciated marker at diagnosis and as a tool for assessing mini-
mal residual disease in AML (Larsen et al, 2012; Roug et al,
2014). Furthermore, CLEC12A has been proposed as a possi-
ble marker for LSC as it can be found on CD34+CD38 cells
in CD34-positive AML, but is completely absent on the
CD34+CD38 compartment in normal donors and in regen-
erating BM (van Rhenen et al, 2007a). In addition, Terwijn
et al (2014) showed that light scatter properties together with
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aberrant marker expression (including CLEC12A) on the
CD34+CD38 cells were able to discriminate leukaemic and
normal stem cell compartments in AML validated by xeno-
graft studies.
Regarding the clonal origin of MDS, the disease entity
has generally been regarded as originating in the
haematopoietic stem cell (HSC), which recent research has
emphasized to hold true also for low-risk MDS (Tehranchi
et al, 2010). Furthermore, for the 5q- syndrome, it has been
shown that, even at an early time point in the course of
the disease, the normal HSC compartment has almost com-
pletely been replaced with clonally expanded stem cells that
are positive for the cytogenetic 5q- aberration (Nilsson
et al, 2007). Woll et al (2014) provided evidence of distinct
cancer stem cells (CSCs) in MDS by tracing all identified
somatic mutations in the bulk BM back to the
immunophenotypically defined Lin-CD34+CD38CD90+
stem cell. Furthermore, this particular stem cell subset was
the only cell type with functional self-renewal potential in
the long-term colony initiating cell (LTC-IC) assay and
hence the ability to maintain and propagate the myelodys-
plastic neoplasm (Woll et al, 2014). While the above men-
tioned studies investigated stem cell subsets defined by the
normal immunophenotypic profile of the HSC, other
research groups have shown aberrant marker-expression on
CD34+CD38 cells in MDS, although only in minor frac-
tions of patients (Florian et al, 2006; Xie et al, 2010; Li
et al, 2014).
Given the formal demonstration of CSCs in MDS (Woll
et al, 2014), and the promising findings of CLEC12A as a
surrogate marker of LSCs in AML (van Rhenen et al, 2007a),
we hypothesized CLEC12A could be used as an immunophe-
notypic marker of CSCs in MDS. Consequently, we examined
the aberrant expression of CLEC12A in the CD34+CD38 cell
compartment in BM from a cohort of MDS patients. Further-
more, to functionally validate the stem cell potential and
malignant nature of these particular cells, we employed a
two-pronged strategy by; i) evaluating the self-renewal prop-
erties of both the CD34+CD38CLEC12A+/ subsets in the
LTC-IC assay and ii) performing interphase fluorescence
in situ hybridization (FISH) analyses of the derived colony-
forming cells (CFCs).
Methods
Patient samples
Bone marrow samples were obtained as excess material taken
as part of the diagnostic process from 31 MDS patients diag-
nosed at the Department of Haematology, Aarhus University
Hospital. The study was conducted in accordance with the
Declaration of Helsinki and was approved by the local ethics
committee. All samples were collected before treatment with
cytoreductive or demethylating agents. MDS diagnoses were
confirmed by morphological examination according to the
2008 World Health Organization (WHO) classification
(Swerdlow et al, 2008). Risk assessment was done according
to the Revised International Prognostic Scoring System
(IPPS-R) (Greenberg et al, 2012). In the immunophenotypic
assay, normal BM (NBM) from 19 healthy volunteers and
BM from 27 AML patients served as negative and positive
controls, respectively.
Flow cytometry
Bone marrow was analysed either fresh (MDS patients 1–19,
NBM 1–11, AML patients 1–8) after red blood cells were
lysed using EasyLyse (DAKO, Glostrup, Denmark) or as
thawed cryopreserved mononuclear cells (MNCs) (MDS
patients 20–31, NBM 12–19, AML patients 9–27). MNCs
were obtained by Lymphoprep (Axis-Shield plc., Dundee,
Scotland) separation according to the manufacturer’s
instructions, cryopreserved in 10% dimethylsulfoxide and
stored in liquid nitrogen. Cryopreserved MNCs were thawed
in a 37°C water bath and resuspended in RoboSep Buffer
(StemCell Technologies, Vancouver, BC, Canada) with 15%
heat inactivated fetal calf serum (Biochrom, GmbH, Berlin,
Germany). Subsequently, cells were stained with the follow-
ing monoclonal antibodies: anti-CD34 allophycocyanin
(Birma-K3), anti-CD38 fluorescein-isothiocyanate (AT 13/5)
(DAKO), anti-CD45 peridinin-chlorophyll-protein-cyanine55
(HI30) (BioLegend, San Diego, CA, USA) and anti-CLEC12A
phycoerythrin (HB3) (own laboratory, courtesy of Gordon
D. Brown). The anti-CLEC12A antibody specificity was pre-
viously validated by Marshall et al (2006) and Larsen et al
(2012). Data acquisition was performed on a FACSCanto II
(BD Biosciences, San Jose, CA, USA) and analysed using
FlowJo Data Analysis Software, version X (FlowJo, Ashland,
OR, USA). In the gating strategy used, the CD34+CD38
population was identified in CD45lowSSClow leucocytes and
analysed for the presence/absence of CLEC12A. The
CLEC12A positive gate was defined using the lymphocytes as
an internal negative control. The CD34+CD38CLEC12A+
population was back-gated and was shown to cluster together
in a forward scatter – side scatter plot. A minimum of five
clustered CD34+CD38CLEC12A+ events was considered sig-
nificant.
Fluorescence activated cell sorting
In four selected MDS patient cases (MDS patients 8, 29, 30
and 31) fluorescence activated cell sorting (FACS) was per-
formed on a BD FACSAriaTM III (BD Biosciences). Cells were
sorted into two subsets, CD45lowSSClowCD34+CD38
CLEC12A+ and CD45lowSSClowCD34+CD38CLEC12A
using the same gating strategy as described above. The
CD45lowSSClowCD34+CD38CLEC12A subset from two
NBMs was sorted as controls. Purity of sorted subsets was
determined in 5 out of 10 subsets due to the rarity of the
cell populations. For the CD45lowSSClowCD34+CD38
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CLEC12A subset, purity was >99% (n = 4; MDS patient 8,
30, and 31, NBM 1). For the CD45lowSSClowCD34+CD38
CLEC12A+ subset, purity was 913% (n = 1; MDS patient
30).
Long-term colony initiating cell assay
Fluorescence activated cell sorted subsets were seeded in up to
four replicates in 96-well collagen-coated plates and cultured
on irradiated (80 Gy) M2-10B4 stromal feeder cells (American
Type Culture Collection [ATCC], Manassas, VA, USA) in
MyeloCult H5100 medium (StemCell Technologies, Vancou-
ver, BC, Canada) supplemented with penicillin-streptomycin
(Gibco, Thermo Fischer Scientific Inc., Waltham, MA, USA)
and 106 mol/l hydrocortisone 21-hemisuccinate (StemCell
Technologies) with weekly half-change of medium. After
6 weeks of co-culture, cells were harvested and transferred to
MethoCult H4435 (StemCell Technologies) for an additional
2 weeks. CFCs were counted and scored for multi-
lineage (colony-forming unit-granulocyte/erythroid/macro-
phage/megakaryocyte (CFU-GEMM)); erythroid (burst-
forming unit - erythrocyte (BFU-E)) and myeloid morphology
[colony-forming unit - granulocyte (CFU-G), colony-forming
unit - macrophage (CFU-M) and colony-forming unit - gran-
ulocyte/macrophage (CFU-GM)]. Ten colonies from each sub-
set of the originally seeded cells were individually picked and
cytospun onto poly-L-lysine coated slides (Thermo Fischer
Scientific Inc., Waltham, MA, USA) and allowed to air-dry for
subsequent FISH analyses.
Interphase fluorescence in situ hybridization
FISH analyses were done according to manufacturer’s
instructions except that all slides containing the cells were
pre-treated with pepsin for 35 min (Histology FISH acces-
sory kit, DAKO, Glostrup, Denmark). The following locus-
specific directly fluorescent-labelled probe set were used:
7pter; D8Z1 (Kreatech, Amsterdam, The Netherlands); MYC
split apart probe (DAKO); D1Z5; LSI EGR1/D5S23,D5S721
and LSI ELN/D7S486,D7S522 (Abbott Molecular, Weiss-
baden, Germany). To estimate the number of FISH-positive
cells, a median of 100 interphase nuclei were evaluated
(range 3–100) by two independent observers. Imaging was
done as described by Kjeldsen and Roug (2012). Cytospin
slides of CFCs from NBM served as negative controls for
each of the specific probes used.
Statistical analyses
All calculations and statistical analyses were conducted with
the use of GraphPad Prism version 6 (GraphPad Software, La
Jolla, CA, USA). The Mann-Whitney test was used to com-
pare the level of CD34+CD38CLEC12A+ in untreated MDS
BM to NMB and AML BM. Kaplan-Meier estimates, together
with the log-rank test were used to study the impact of a
detectable fraction of CLEC12A+ cells in the CD34+CD38
cell compartment on overall survival (OS) and AML-free sur-
vival. OS was calculated from the sampling date to the date of
death by any cause. AML-free survival was calculated from
the sampling date to the date of progression to AML or death
by any cause. P < 005 was considered significant.
Results
Demographic data
The median age of the MDS patients was 69 years (range
29–83 years) at the time of sampling. The MDS subtype
according to the 2008 WHO Classification, karyotype, IPSS-
R risk group as well as AML-free survival are depicted in
Table I. As evident herein, all subtypes of MDS were repre-
sented and the patients were distributed across all IPSS-R
risk groups. Seventeen patients (55%) presented with a nor-
mal karyotype, which is in accordance with the literature
(Bejar & Steensma, 2014).
CLEC12A is aberrantly expressed on the MDS stem cell
subset
We initially set out to determine the immunophenotypic
profile of the stem cell subset CD45lowCD34+CD38 with
regards to co-expression of CLEC12A. The gating strategy for
the assay is depicted in Fig 1A. Consistent with previous
findings (van Rhenen et al, 2007a), CLEC12A was completely
absent on the CD34+CD38 cell compartment in all of the
19 NBM examined (00%). In contrast, we found CLEC12A
to be aberrantly expressed on the CD34+CD38 cell subset
in 71% (22/31) of MDS cases. In myeloid neoplasms, the
presence of several malignant subclones and evidence of clo-
nal evolution during the course of disease have been studied
by several groups (Fialkow et al, 1991; Walter et al, 2012).
Thus, we found it appealing to investigate the aberrant
CD34+CD38CLEC12A+ subset as a fraction of the imma-
ture CD34+CD38 cells. Applying this method, the median
percentage of aberrant cells as a fraction of the CD34+CD38
subset was 41% (range 00–567%), which was significantly
different from NBM (P < 00001).
Similarly, for the AML control samples, we determined the
fractions of the CLEC12A+ subsets as a percentage of the
CD34+CD38 subset. In CD34-positive AML (n = 21) (de-
fined as >2% CD34+ cells of the blast population), the percent-
age of CLEC12A-positive CD34+CD38 cells amounted a
median of 131% (range 00–589%), which was significantly
different from NBM (P < 00001), but not from MDS BM
(P = 008) (Fig 1B). In BM samples with a detectable
CLEC12A+ fraction of the CD34+CD38 cells, there was no
significant difference in median fluorescence intensity of
CLEC12A between CD34-positive AML and MDS (P = 012).
As expected, expression of CLEC12A was not found on the
CD34+CD38 cells in CD34-negative AML (n = 6) (Fig 1B).
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Hence, although with a p-value approaching significance in
favour of a higher amount of CLEC12A expressing
CD34+CD38 cells in CD34+ AML, in our cohort the level of
this particular cell subset is seemingly comparable in MDS and
CD34+ AML. When we evaluated the expression of CLEC12A
on the CD34+CD38 compartment across IPPS-R risk groups,
we found it to be present in all of these and thus not restricted
to cases with excess blasts or high-risk MDS (Fig 1C).
Collectively, the immunophenotypic data support the
hypothesis of CLEC12A as an aberrantly expressed marker
on the stem cell subset in MDS. Furthermore, this finding
was not restricted to high risk MDS or MDS with excess
blasts, as could be surmised from the established fact of
CLEC12A as a marker of blasts and LSCs in AML, suggesting
a role for this marker in the broad spectrum of myelodys-
plastic disorders.
The CD34+CD38CLEC12A+ cells are malignant and
possess self-renewal potential
While the above-described data clearly infers that CLEC12A
can be expressed on stem cells in MDS, this does not consti-
tute definite evidence of the functional stem cell properties
or the malignancy of these particular cells. Primary human
MDS cells grow poorly in most mouse models and highly
specific and genetically engineered mouse models are
required to study human MDS in the xenograft setting
(Zhou et al, 2015). Consequently, to functionally assess the
self-renewal potential of both the CLEC12A positive
CD34+CD38 cells and the CD34+CD38 cells lacking
CLEC12A expression, four MDS patients with known clonal
cytogenetic abnormalities were selected for studies in the
LTC-IC assay. The cytogenetic abnormalities of the patients
Table I. Patient characteristics.
Patient no. WHO subtype
Clonal chromosomal
abnormalities detected
IPSS-R
Risk group
CD34+CD38CLEC12A+/
CD34+CD38
AML-free
survival (d)
1 RAEB-1 No aberrations LOW 0%
2 RAEB-1 No aberrations INT 0% 605
3 RCMD No aberrations V-LOW 0%
4 RCUD +8 LOW 379% 1169
5 RAEB-1 inv(3)(p12q26) V-HIGH 63% 583
6 RAEB-1 No aberrations INT 567% 16
7 RCUD Complex INT 0%
8 RAEB-1 +del(1)(p13), +8 INT 15% 658
9 RCUD No aberrations V-LOW 174% 154
10 NA* ND NA 18% 713
11 Hypo RCUD No aberrations LOW 41% 91
12 RAEB-1 No aberrations HIGH 0%
13 RAEB-1 No aberrations INT 64%
14 RCUD -X INT 226%
15 RCUD No aberrations LOW 116%
16 RCUD No aberrations V-LOW 147%
17 RARS No aberrations LOW 0%
18 MDS-U No aberrations LOW 32% 210
19 RAEB-2 No aberrations HIGH 43%
20 RCUD del(15)(q22q26) HIGH 56%
21 RAEB-2 Complex, incl. del(5q)(q13q33),-7 V-HIGH 06% 55
22 RCUD -7 INT 56%
23 RCUD No aberrations LOW 12%
24 RCUD No aberrations V-LOW 68% 405
25 MDS-U +mar LOW 0% 670
26 RCUD No aberrations INT 0% 554
27 RCUD -Y V-LOW 0%
28 RCUD No aberrations V-LOW 74%
29 RCUD +8 INT 120% 482
30 RCMD Complex, incl. -5, -7 NA* 174%
31 Del(5q) del(5)(q13q31) INT 01%
AML, acute myeloid leukaemia; INT, intermediate; IPSS-R, Revised International Prognostic Scoring System; MDS-U, myelodysplastic syndrome
– unclassified; NA, not applicable; ND, not done; RAEB-1, refractory anaemia with excess blasts type 1; RAEB-2, refractory anaemia with excess
blasts type 2; RARS, refractory anaemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory
cytopenia with unilineage dysplasia; V-HIGH, Very High; V-LOW, Very Low; WHO, World Health Organization.
*Insufficient material for complete morphological evaluation.
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Fig 1. CLEC12A expression on the CD34+CD38 stem cell subset. (A) Gating strategy (MDS Patient 9). In the first panel, the CD45low/SSClow
population was defined. Next, the CD34+CD38 population was gated and analysed for the presence/absence of CLEC12A. The last panel shows
the CD34+CD38CLEC12A+ population back-gated into the CD34+CD38 plot. (B) CLEC12A expression on the CD34+CD38 cell subset in
normal bone marrow (NBM), myelodysplastic syndrome (MDS), CD34-positive (CD34+) acute myeloid leukaemia (AML) and CD34-negative
(CD34) AML, respectively. (C) CLEC12A expression on the CD34+CD38 cell subset according to IPSS-R risk groups. Filled symbols indicate
later progression to AML.
Table II. Results from LTC-IC and subsequent FISH analyses.
Patient
Targeted chromosomal
aberrations
(FISH probe locus) Sorted subsets
Seeded
in LTC-IC
CFC count*
FISH positivityErythroid Myeloid
MDS 8 +1q (CEP1)
and +8 (SE8)
CD34+CD38CLEC12A+ 19 0 24 10/10 (100%)
CD34+CD38CLEC12A 500 1 410 10/10 (100%)
MDS 29 +8 (MYC) CD34+CD38CLEC12A+ 146 0 40 7/7 (100%)
CD34+CD38CLEC12A 500 2 34 2/10 (20%)†
MDS 30 -5 (EGR1) and -7
(D7S486,D7S522)
CD34+CD38CLEC12A+ 500 0 245 10/10 (100%)
CD34+CD38CLEC12A 500 0 438 10/10 (100%)
MDS 31 -5 (EGR1) CD34+CD38CLEC12A+ 123 0 1‡ No cells
CD34+CD38CLEC12A 500 0 63 7/7 (100%)
NBM 1 (CEP1), (SE8) CD34+CD38CLEC12A 500 2 19 No aberrations¶
NBM 2 (EGR1),
(D7S486,D7S522)
CD34+CD38CLEC12A 500 4 28§ No aberrations¶
CFC, colony-forming cell; CFU-GEMM, colony-forming unit-granulocyte/erythroid/macrophage/megakaryocyte; FISH, fluorescence in situ
hybridization; LTC-IC, long-term colony initiating cell assay; MDS, myelodysplastic syndrome; NBM, normal bone marrow.
*Mean CFC count of 2–3 plates normalized to 500 cells, when ≥500 cells originally seeded in LTC-IC.
†FISH-negative CFCs were morphologically normal.
‡Scattered cells.
§In addition 1 CFU-GEMM.
¶NBM served as negative controls for all of the applied FISH-probes.
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are depicted in Table II together with the number of seeded
cells from each sorted cell subset, CFC counts and origin
(erythroid/myeloid), and FISH results.
When we examined and harvested the single colonies
derived from LTC-IC, we observed that CFCs from MDS
patients (both CLEC12A+ and CLEC12A subsets) were
morphologically abnormal and smaller than those from nor-
mal controls and were almost exclusively of non-erythroid
origin (Fig 2A and B). Interestingly, erythroid CFCs were
never present in the CD34+CD38CLEC12A+ subset in any
of the 4 MDS patients studied in LTC-IC. This is in line with
the general perception of CLEC12A as a myeloid marker.
In all harvested colonies analysed by FISH, 100% of CFCs
from the CD34+CD38CLEC12A+ subsets were of malignant
origin as evidenced by the presence of specific cytogenetic
aberrancies (Table II). Interestingly, for MDS Patient 29,
CFCs from the CD34+CD38CLEC12A subset were a mix-
ture of the aforementioned abnormal small colonies and
morphologically normal CFCs. This observation was sup-
ported by and in accordance with the FISH results because
the small abnormal CFCs were positive for trisomy 8 and the
morphologically normal CFCs presented with a normal kary-
otype (Table II). In the remaining samples examined in
LTC-IC, CFCs originating from the CD34+CD38CLEC12A
subsets were also 100% malignant when cytogenetically eval-
uated by FISH (Fig 2C). Overall, the data from the LTC-IC
studies showed the CD34+CD38CLEC12A+ to possess self
renewal properties and that these particular cells are 100%
malignant when evaluated by FISH for known cytogenetic
aberrancies, adding support to the concept of CLEC12A as a
marker of malignant CSC subsets in MDS.
The presence of CD34+CD38CLEC12A+ cells and
survival
Given that CLEC12A was expressed on CD34+CD38 cells
across all IPSS-R risk groups, we looked at the impact of these
cell subsets on the clinical course of the patients studied. The
median follow up time was 659 d (range 56–2926 d). Progres-
sion to AML occurred in 45% (14/31) of cases, and 79% (11/
14) of these had a detectable CD34+CD38CLEC12A+ frac-
tion at the time of sampling (Table I). Survival analysis
showed no correlation between the detection of CLEC12A
expression on CD34+CD38 cells and neither OS (P = 050)
nor AML-free survival (P = 012).
Discussion
The present study showed that, as in AML, CLEC12A is pre-
sent on the CD34+CD38 cell compartment in the majority
of the 31 MDS cases studied. Moreover, CLEC12A could be
found expressed on a fraction of the CD34+CD38 cells in
(A)
(C)
(B)
Fig 2. LTC-IC and confirmatory FISH. (A)
Representative colony-forming cells (CFC)
from the CD34+CD38CLEC12A+ subset in
MDS Patient 30. The colony is smaller and
contains fewer cells than myeloid colonies from
normal bone marrow (NBM). (B) Representa-
tive CFC from NBM. (C) Confirmatory fluo-
rescence in situ hybridization using the D1Z5
probe (red) and centromeric D8Z1 probe
(green) confirming the trisomy 1 and 8 aberra-
tions (MDS Patient 8) in interphase nuclei
(3R3G signal pattern) in a cell from the
CD34+CD38CLEC12A+ and
CD34+CD38CLEC12A derived colonies,
respectively.
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all WHO subtypes of MDS and across the IPPS-R risk
groups. The percentage of CLEC12A+ cells in the
CD34+CD38 compartment in MDS was comparable to the
level found in CD34-positive AML. Conversely, expression of
CLEC12A was not found on the CD34+CD38 cells in
CD34-negative AML, which is consistent with previous find-
ings indicating that in CD34-negative AML, the small frac-
tion of CD34-positive cells in most cases represents normal
HSCs (van der Pol et al, 2003; Taussig et al, 2010). Further-
more, and importantly, we showed that the
CD34+CD38CLEC12A+ cells are indeed malignant and pos-
sess functional stem cell properties in terms of self-renewal
when evaluated in the LTC-IC assay.
In AML, evidence of the ability of CLEC12A to distinguish
between the LSC and its normal counterpart, the HSC, was,
to a certain extent, raised by van Rhenen et al (2007a,b),
who showed that sorted CD34+CD38CLEC12A+ cells were
malignant by FISH, while the CD34+CD38CLEC12A
cells proved negative for the AML-specific cytogenetic
abnormalities. Furthermore, malignant engraftment of
CD34+CLEC12A+ cells in non-obese diabetic/severe com-
bined immunodeficiency (NOD/SCID) mice was demon-
strated. The immunophenotypic studies included patients
with refractory anaemia with excess blasts (RAEB) and RAEB
in transformation [defined by the French-American-British
(FAB) classification (Bennett et al, 1982)], while the FISH
analyses and the engraftment studies were done only on
AML samples (van Rhenen et al, 2007a,b). Thus, to the best
of our knowledge, functional studies of CLEC12A as a mar-
ker of CSCs in MDS have not been performed up until now.
In the present study, we have corroborated the immunophe-
notypic findings of van Rhenen et al (2007a,b) by confirming
the possible aberrant expression of CLEC12A on the
CD34+CD38 stem cell subset from MDS patients. In addi-
tion, we have extended these findings; firstly by demonstrat-
ing aberrant CD34+CD38CLEC12A+ cells in all MDS
subtypes defined by the current 2008 WHO classification and
across all IPSS-R risk groups, hence providing evidence that
this phenomenon is not restricted to high-risk MDS or MDS
with excess blasts. This suggests CLEC12A to have an inde-
pendent role as a CSC marker in MDS and not solely associ-
ated with AML, high-risk MDS or MDS in transformation to
AML. Secondly, by performing functional LTC-IC studies,
we observed notable differences between MDS and the
previous findings in AML. As colonies derived from
CD34+CD38CLEC12A cells were predominantly malig-
nant, CLEC12A was not able to distinguish between normal
HSCs and CSCs, which might reflect important differences in
disease biology between the two disease entities. Whereas
MDS has been shown to originate from the earliest
haematopoietic stem cell (Lin-CD34+CD38CD90+) (Woll
et al, 2014), recent evidence suggest the majority of AML
cases to propagate from more mature progenitors (Mora-
Jensen et al, 2015). Furthermore, in AML more than one
LSC population can co-exist in the same patient and be
hierarchically ordered (Goardon et al, 2011). Speculatively,
in MDS, CD34+CD38CLEC12A+ cells could be a distinct
CSC population downstream in a CSC hierarchy.
Our results from the LTC-IC experiments therefore sup-
port the prevailing concept of MDS originating in the
CD34+CD38 subset. Interestingly, in the case of MDS
Patient 29 only 20% of the CD34+CD38CLEC12A CFCs
were trisomy 8 positive, indicating a relatively large propor-
tion of remaining normal HSCs in the BM of this particu-
lar patient. In line with this finding, Woll et al (2014)
showed the frequency of Lin-CD34+CD38CD90+ cells har-
bouring the trisomy 8 aberration to be < 80%, while for
the 5q- cases the stem cell compartment was almost
entirely replaced by the malignant clone. Thus, our results
also substantiate that residual normal HSCs - if present -
are always contained in the CD34+CD38CLEC12A cell
subset.
Importantly, given the complete absence of CLEC12A on
normal CD34+CD38 cells, evaluating CLEC12A expression
on CD34+CD38 cells might be a useful diagnostic tool in
MDS, representing a “different from normal”-approach.
Diagnosis of MDS stays a challenge and our study shows that
CD34+CD38CLEC12A+ cells are also present in cases that
are in the very low or low IPSS-R risk groups. Thus, moni-
toring CLEC12A expression on the CD34+CD38 compart-
ment longitudinally in a cohort of ICUS patients could add
important knowledge to the diagnostic value of this easily
applicable flow cytometry-based assay.
Several recent studies have investigated the intraclonal
heterogeneity in various myeloid malignancies. Using whole
genome sequencing of myeloblasts from secondary AML
(sAML) with subsequent deep resequencing of paired skin,
MDS and sAML samples, Walter et al (2012) showed MDS
and sAML to be highly oligoclonal with outgrowth of smaller
MDS clones acquiring additional mutations at the time of
progression to sAML. In addition, Lindsley et al (2015)
recently examined 17 paired MDS/sAML samples and found
AML-related mutations in myeloid transcription factor and
signalling genes down to an allele frequency of 1% at the
time of MDS (Lindsley et al, 2015). Thus, studying even
minute fractions of stem cells with aberrant expression of,
for example, CLEC12A by flow cytometry could be of high
relevance considering this pronounced intraclonal diversity
in the myelodysplastic neoplasm. In this regard, future stud-
ies are warranted to evaluate the possible genetic/epigenetic
differences between the CD34+CD38CLEC12A+/ subsets in
MDS. One interesting approach would be studies to evaluate
if CLEC12A positive CSCs are more prone to transformation
to AML, e.g. through activated proliferative pathways and/or
a different mutational status. Such studies might also shed
light on a possible functional role of CLEC12A in myeloid
neoplasms.
The most interesting hallmark of CLEC12A is its absence
on the CD34+CD38 cell subset from normal donors. Conse-
quently, CLEC12A has been proposed as a potential target in
CLEC12A is Expressed on MDS Cancer Stem Cells
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the future treatment of AML because residual normal HSCs
would be spared. Basic research is currently investigating dif-
ferent approaches in this regard: for example, Lu et al (2014)
developed a novel immunotherapeutic bispecific antibody for
the recruitment of cytotoxic T-cells to CLEC12A-positive
AML cells. As mentioned, our results show that CLEC12A
does not have the potential of distinguishing CSCs from their
normal counterparts in MDS. Despite this, the
CD34+CD38CLEC12A+ cells might represent a more prolif-
erative subclone in the pool of malignant cells. Hence specu-
latively, targeting CLEC12A in MDS would not eradicate all
malignant clones, but could theoretically target a potentially
more aggressive subclone.
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